234 related articles for article (PubMed ID: 20146086)
1. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
Clarke JL; Pao W; Wu N; Miller VA; Lassman AB
J Neurooncol; 2010 Sep; 99(2):283-6. PubMed ID: 20146086
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
[TBL] [Abstract][Full Text] [Related]
3. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Grommes C; Oxnard GR; Kris MG; Miller VA; Pao W; Holodny AI; Clarke JL; Lassman AB
Neuro Oncol; 2011 Dec; 13(12):1364-9. PubMed ID: 21865399
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Togashi Y; Masago K; Masuda S; Mizuno T; Fukudo M; Ikemi Y; Sakamori Y; Nagai H; Kim YH; Katsura T; Mishima M
Cancer Chemother Pharmacol; 2012 Sep; 70(3):399-405. PubMed ID: 22806307
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
[TBL] [Abstract][Full Text] [Related]
7. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
9. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
[TBL] [Abstract][Full Text] [Related]
10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
11. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Lee Y; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
J Neurooncol; 2013 Oct; 115(1):95-101. PubMed ID: 23832498
[TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
Wagner M; Besse B; Balleyguier C; Soria JC
J Thorac Oncol; 2008 Jun; 3(6):677-9. PubMed ID: 18520813
[No Abstract] [Full Text] [Related]
13. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
15. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
Fukuhara T; Saijo Y; Sakakibara T; Inoue A; Morikawa N; Kanamori M; Nakashima I; Nukiwa T
Tohoku J Exp Med; 2008 Apr; 214(4):359-63. PubMed ID: 18441512
[TBL] [Abstract][Full Text] [Related]
17. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
